文献速递皮肤肿瘤

黑色素瘤中突变的MITF-E87R通过S100A4增强肿瘤进展

Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
PubMed 文献 · J Invest Dermatol · 2018-04-19

该研究通过对表达突变型MITF的细胞进行转录组无偏分析,发现钙结合蛋白S100A4是MITF-E87R的下游靶点。在野生型和突变型MITF黑色素瘤细胞系中,野生型MITF抑制S100A4表达,而MITF-E87R激活其转录,导致MITF-E87R通过S100A4增强侵袭并降低黏附。S100A4表达改变的黑色素瘤患者预后不良。

要点

  • MITF-E87R突变将MITF对S100A4的转录调控由抑制转为激活。
  • MITF-E87R通过S100A4增强黑色素瘤细胞侵袭并降低黏附。
  • S100A4表达改变的黑色素瘤患者预后不良。

核心结论

  • MITF点突变导致其转录活性从抑制S100A4变为激活S100A4,从而改变黑色素瘤侵袭能力。
  • 这些数据提示了转移性黑色素瘤诊断和治疗的新机会。

研究设计与样本

  • 研究对表达突变型MITF的细胞进行转录组无偏分析,并使用野生型和突变型MITF黑色素瘤细胞系进行实验。
  • 研究分析了黑色素瘤患者的S100A4表达与预后。

主要发现

  • S100A4被鉴定为MITF-E87R的下游靶点。
  • 内源性野生型和MITF-E87R变异体均占据S100A4启动子。
  • 野生型MITF抑制S100A4表达,而MITF-E87R激活其转录。
  • MITF-E87R通过S100A4增强侵袭并降低黏附,与野生型MITF活性相反。
  • S100A4表达改变的黑色素瘤患者预后不良。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Melanoma, a melanocyte origin neoplasm, is the most lethal type of skin cancer, and incidence is increasing. Several familial and somatic mutations have been identified in the gene encoding the melanocyte lineage master regulator, MITF; however, the neoplastic mechanisms of these mutant MITF variants are mostly unknown. Here, by performing unbiased analysis of the transcriptomes in cells expressing mutant MITF, we identified calcium-binding protein S100A4 as a downstream target of MITF-E87R. By using wild-type and mutant MITF melanoma lines, we found that both endogenous wild-type and MITF-E87R variants occupy the S100A4 promoter. Remarkably, whereas wild-type MITF represses S100A4 expression, MITF-E87R activates its transcription. The opposite effects of wild-type and mutant MITF result in opposing cellular phenotypes, because MITF-E87R via S100A4 enhanced invasion and reduced adhesion in contrast to wild-type MITF activity. Finally, we found that melanoma patients with altered S100A4 expression have poor prognosis. These data show that a change in MITF transcriptional activity from repression to activation of S100A4 that results from a point mutation in MITF alters melanoma invasive ability. These data suggest new opportunities for diagnosis and treatment of metastatic melanoma.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Nordlinger A, Dror S, Elkahloun A, et al. Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4. J Invest Dermatol. 2018. PMID: 29679610. doi:10.1016/j.jid.2018.03.1524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。